Abstract: A scanning confocal microscopy system and apparatus, especially useful for endoscopy with a flexible probe which is connected to the end of an optical fiber (9). The probe has a grating (12) and a lens (14) which delivers a beam of multi-spectral light having spectral components which extend in one dimension across a region of an object and which is moved to scan in another dimension. The reflected confocal spectrum is measured to provide an image of the region.

Abstract: A modified adenovirus capable of overcoming the problem of low level of coxsackle-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to mutations in E1a or E1b genes.

Abstract: The invention provides a method of sensitizing target cells to ultrasound energy using a stimulus such as an electric field. This “electrosensitisation” enables target cells to be disrupted by ultrasound at frequencies and energies of ultrasound which do not cause disruption of non-sensitized (i.e., non-target) cells. As a consequence, the method increases the selectivity of ultrasound therapy, providing a way to ablate undesired cells, such as diseased cells (e.g., tumor cells) while minimizing harm to neighboring cells. In another aspect, however, ultrasound can be used to sensitize cells while the electrical field is used to disrupt cells. The invention also provides an apparatus for performing the method and assays for identifying gene products and other molecules involved in apoptosis.

Abstract: A retroviral delivery system capable of transducing a target site is described. The retroviral delivery system comprises a first nucleotide sequence coding for at least a part of an envelope protein; and one or more other nucleotide sequences derivable from a retrovirus that ensure transduction of the target site by the retroviral delivery system; wherein the first nucleotide sequence is heterologous with respect to at least one of the other nucleotide sequences; and wherein the first nucleotide sequence codes for at least a part of a rabies G protein or a mutant, variant, derivative or fragment thereof that is capable or recognising the target site.

Abstract: Disclosed and claimed are compositions for inducing in a bovine host an immunological response against bovine respiratory syncytial virus or bovine viral diarrhea virus containing at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine respiratory syncytial virus F protein, or G protein, or F and G proteins; or, at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine viral diarrhea virus E2 protein, or C, E1 and E2 proteins, or E1 and E2 proteins. Methods and kits employing such compositions are also disclosed.

Abstract: All Borrelia burgdorferi sensu lato isolates characterized to date have one or a combination of several major outer surface proteins (Osp). Mutants of B. burgdorferi lacking Osp proteins were selected with polyclonal or monoclonal antibodies at a frequency of 10−6 to 10−5. One mutant that lacked OspA, B, C and D was further characterized in the present study. It was distinguished from the OspA+B+ cells by its (i) auto-aggregation and slower growth rate, (ii) decreased plating efficiency on solid medium, (iii) serum- and complement-sensitivity, and (iv) diminished capacity to adhere to human umbilical vein endothelial cells. The Osp-less mutant was unable to evoke a detectable immune response after intradermal live cell immunization even though mutant survived in the skin the same duration as wild-type cells.

Abstract: The utility of adenovirus vectors (Ad) for gene therapy is restricted by their inability to selectively transduce disease-affected tissues. This limitation may be overcome by the derivation of vectors capable of interacting with receptors specifically expressed in the target tissue. Previous attempts to alter Ad tropism by genetic modification of the Ad fiber have had limited success due to structural conflicts between the fiber and the targeting ligand. The present invention presents a strategy to derive an Ad vector with enhanced targeting potential by a radical replacement of the fiber protein in the Ad capsid with a chimeric molecule containing a heterologous trimerization motif and a receptor-binding ligand.

Abstract: The invention relates to a method for selectively releasing an agent loaded into a red blood cell, comprising electrosensitizing the red blood cell by application of an electric field and subsequently disrupting the cell selectively using ultrasound.

Abstract: A retroviral vector is described. The retroviral vector comprises a functional splice donor site and a functional splice acceptor site; wherein the functional splice donor site and the functional splice acceptor site flank a first nucleotide sequence of interest (“NOI”); wherein the functional splice donor site is upstream of the functional splice acceptor site; wherein the retroviral vector is derived from a retroviral pro-vector; wherein the retroviral pro-vector comprises a first nucleotide sequence (“NS”) capable of yielding the functional splice donor site and a second NS capable of yielding the functional splice acceptor site; wherein the first NS is downstream of the second NS; such that the retroviral vector is formed as a result of reverse transcription of the retroviral pro-vector.

Abstract: Disclosed and claimed is the use of a liquid jet intradermal administration apparatus that administers a composition: without a needle; and in the epidermis, dermis and/or hypodermis, such as a Pigjet apparatus, for administering bovine vaccines or immunogenic compositions, especially bovine plasmid vaccines or immunogenic compositions. Accordingly, the invention involves bovine immunogenic or vaccine compositions in such an apparatus, and methods for vaccinating bovines or for inducing an immunogenic response in bovines employing such an apparatus, as well as the apparatus containing bovine immunogenic or vaccine compositions.

Abstract: Disclosed and claimed are methods for treating or preventing neurodegenerative diseases, conditions or maladies or symptoms or physiology associated therewith, such as treating or preventing Parkinson's disease or symptoms or physiology associated therewith such as motor deficits or nigrostriatal degeneration; or, for inducing nigrostriatal regeneration. Advantageously, the methods involve administering a lentiviral vector that expresses GDNF, such as human GDNF, or a variant, homolog, analog or derivative thereof.

Abstract: In preferred aspects the present invention provides: (i) a method of and apparatus for depositing material, preferably a film, on a substrate, the method comprising the steps of: providing a substrate; heating the substrate; generating an aerosol comprising droplets of a material solution; providing a nozzle unit for delivering the aerosol to the substrate, the nozzle unit including at least one outlet through which a directed flow of the aerosol is delivered and at least one electrode; charging the aerosol droplets with a positive or negative charge; providing a flow of the aerosol through the nozzle unit so as to deliver a directed flow of the aerosol from the at least one outlet; and generating an electric field between the substrate and the at least one electrode such that the directed aerosol flow is attracted towards the substrate; and (ii) a method of and apparatus for fabricating a powder, preferably an ultrafine powder, the method comprising the steps of: providing a heated zone; generating an aeroso

Abstract: A spot-on composition for the treatment or protection of a domestic animal against parasitic infestation comprising, (a) an insecticidal active substance of the formula (X): (b) an organic solvent; and (c) a vehicle; and (d) an emollient; wherein the composition comprises from 0.05 to 25% weight/volume of the compound of formula (X), and the compound of formula (X) is applied in a dose between 0.1 and 2 mg/kg animal weight.

Abstract: This invention provides for a pharmaceutical or veterinary paste formulation comprising: an effective amount of a therapeutic agent; fumed silica; a viscosity modifier; a hydrophilic carrier; optionally, an absorbent; and optionally, a colorant, stabilizer, surfactant, or preservative. This invention also provides for methods of using these formulations for treating various disease states as well.

Abstract: A viral vector production system is provided which system comprises: (i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles, (ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product; wherein at least one of the gene products is an external guide sequence capable of binding to and effecting the cleavage by RNase P of the second nucleotide sequence.

Abstract: A confocal microscope system that is inherently fiberoptic compatible is described which has line scanning aided image formation. An incoherent fiberoptic bundle maps a line illumination pattern into a dispersible group of separate sources, and then remaps this confocally selected remitted light to the original line. Fibers, not confocal with the illumination, carry light to be rejected from the image back on itself upon double passing, while separate fibers carry light from non-confocal sample planes. The transformation allows efficient rejection of unwanted photons at a slit aperture. The fiber bundle and an objective lens provide a flexible probe for imaging internal tissue for pathological examination on a cellular level.

Abstract: There is provided a composition comprising i) a pigment ii) a compound having the formula wherein R1, R2 and R3 are independently selected from an acyl group or a hydrogen atom, wherein at least one of R1, R2 and R3 is an acyl group (a short acyl group) having from 2 to 5 carbon atoms, wherein at least one of R1, R2 and R3 is a branched chain acyl group (a long acyl group) consisting of a chain having 10 to 20 carbon atoms and a hydrophilic branch group.

Abstract: There is provided composition comprising i) a thermoplastic polymer ii) a compound having the formula wherein R1, R2 and R3 are independently selected from an acyl group or a hydrogen atom, wherein at least one of R1, R2 and R3 is an acyl group (a short acyl group) having from 2 to 6 carbon atoms, wherein at least one of R1, R2 and R3 is a branched chain acyl group (a long acyl soup) consisting of a saturated chain having 10 to 20 carbon atoms and a hydrophilic branch group.

Abstract: A change in viral tropism occurs in many HIV positive individuals over time and can be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus can be shifted back to CCR5-mediated entry after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CXCR4 specific strains. The diagnostic methods can be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time.

Abstract: Disclosed and claimed are methods of non-invasive genetic immunization in an animal and/or methods of inducing a systemic immune or therapeutic response in an animal, products therefrom and uses for the methods and products therefrom. The methods can include contacting skin of the animal with a vector in an amount effective to induce the systemic immune or therapeutic response in the animal. The vector can include and express an exogenous nucleic acid molecule encoding an epitope or gene product of interest. The systemic immune response can be to or from the epitope or gene product. The nucleic acid molecule can encode an epitope of interest and/or an antigen of interest and/or a nucleic acid molecule that stimulates and/or modulates an immunological response and/or stimulates and/or modulates expression, e.g., transcription and/or translation, such as transcription and/or translation of an endogenous and/or exogenous nucleic acid molecule; e.g.